Base editors reshape pathogenic repeats
CMN Briefs
May. 27, 2025
Relevant Interviews, Webinar and Trial Updates posted by CRISPR Medicine News.
Always stay updated with the free CMN Newsletter.
Feldan Therapeutics
Company type: Therapeutics
Main focus: Proprietary peptide-based delivery technology called Feldan Shuttle.
Company stage: Pre-clinical
Diseases: Basal cell carcinoma
Genome-editing tool: CRISPR-Cas
Funding stage: Grant II
Location: Quebec, Qc, Canada
Website: https://www.feldan.com/about
Pipeline: https://www.feldan.com/therapeutic-focus
Partners: Elasmogen
Feldan Therapeutics is a biotech company specialising in the development of novel therapies using a proprietary peptide-based delivery technology called Feldan Shuttle. The Feldan Shuttle technology enables efficient intracellular delivery of various molecules, including proteins, antibodies, and nucleic acids.
